{"i": ["chemoimmunotherapy", "bevacizumab"], "o": []}
{"i": [], "o": []}
{"i": ["Bevacizumab"], "o": []}
{"i": [], "o": []}
{"i": ["bevacizumab ( PCR - B )", "pentostatin , cyclophosphamide and rituximab ( PCR )"], "o": []}
{"i": ["PCR", "PCR - B"], "o": []}
{"i": [], "o": ["rate of grade 3 - 4 cardiovascular toxicity"]}
{"i": ["PCR - B"], "o": ["progression - free survival ( PFS )(", "complete remission ( CR ) rate", "treatment - free survival ( TFS )("]}
{"i": ["bevacizumab ."], "o": ["PFS and TFS"]}
{"i": [], "o": ["CR", "baseline CCL - 3 levels", "VEGF levels"]}
{"i": ["bevacizumab"], "o": ["PFS and TFS ."]}
{"i": ["chemoimmunotherapy ( CIT )"], "o": ["treatment free survival", "complete remission ( CR", "overall survival", "response rates"]}
{"i": [], "o": ["CR rates", "residual disease"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["Bevacizumab"], "o": []}
{"i": ["bevacizumab"], "o": ["clinical activity"]}
{"i": ["chemotherapy", "bevacizumab"], "o": []}
{"i": ["CIT", "anti - VEGF therapy"], "o": ["VEGF levels"]}
{"i": ["pentostatin , cyclophosphamide , and rituximab with ( PCR )", "anti - VEGF agent , bevacizumab ( PCR - B ), or without bevacizumab ( PCR )"], "o": []}
{"i": [], "o": []}
{"i": ["PCR", "PCR - B"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["13q14"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["PCR", "PCR - B"], "o": []}
{"i": ["PCR - B"], "o": ["patient choice , infectious complication ( pneumonia ) and cardiovascular complications ( hypertension , myocardial ischemia , congestive heart failure , and aortic dissection );", "pneumonia , nausea , neurological symptoms , and treating physician choice ."]}
{"i": ["pentostatin and cyclophosphamide ."], "o": ["dose delay"]}
{"i": ["Bevacizumab"], "o": ["hypertension , need for polypectomy , and proteinuria"]}
{"i": ["Bevacizumab"], "o": ["febrile neutropenia", "central nervous system hemorrhage ."]}
{"i": [], "o": []}
{"i": [], "o": ["adverse events"]}
{"i": ["PCR - B"], "o": ["grade 3 + event"]}
{"i": ["PCR - B"], "o": ["grade 4 + event"]}
{"i": [], "o": ["hypertension", "left ventricular failure", "Grade 3 - 4 cardiovascular toxicity", "left ventricular dysfunction", "myocarditis"]}
{"i": [], "o": ["Non - heme toxicity", "Grade 3 + Heme toxicity", "Hemoglobin decrease", "Neutropenia", "3 + toxicity", "Thrombocytopenia"]}
{"i": [], "o": []}
{"i": [], "o": ["response", "CR or CR with incomplete marrow recovery ( CR - i"]}
{"i": [], "o": ["response"]}
{"i": [], "o": ["CR / CR - i"]}
{"i": [], "o": ["MRD - negative remission"]}
{"i": [], "o": ["achievement of CR / CR - i or MRD eradication"]}
{"i": [], "o": []}
{"i": ["PCR - B"], "o": []}
{"i": ["PCR - B"], "o": ["median PFS"]}
{"i": ["PCR - B"], "o": []}
{"i": [], "o": ["Median TFS"]}
{"i": [], "o": []}
{"i": [], "o": ["Median OS"]}
{"i": ["bevacizumab"], "o": ["TFS", "PFS"]}
{"i": [], "o": []}
{"i": [], "o": ["Median levels of VEGF , b - FGF , TSP - 1 , CCL - 3 and CCL - 4"]}
{"i": [], "o": ["Plasma cytokine kinetics"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["PCR"], "o": []}
{"i": [], "o": ["CCL - 3 , CCL - 4 , TSP - 1 and / or b - FGF"]}
{"i": [], "o": ["CCL - 4 levels", "baseline values of CCL - 3", "CR / CR - i"]}
{"i": [], "o": []}
{"i": [], "o": ["cytokine plasma levels and responses"]}
{"i": ["CIT", "anti - VEGF therapy"], "o": []}
{"i": ["chemoimmunotherapy", "bevacizumab"], "o": ["hypertension", "non - fatal cardiovascular complications", "hypertensive emergency", "torsade", "severe adverse events", "cardiovascular complication", "myocarditis", "CHF"]}
{"i": ["PCR", "anti - VEGF therapy"], "o": ["complete remission rate"]}
{"i": [], "o": []}
{"i": ["bevacizumab"], "o": ["MRD eradication rate", "PFS and TFS ."]}
{"i": ["bevacizumab"], "o": ["median PFS and TFS", "disease - free survival"]}
{"i": ["anti - VEGF therapy"], "o": []}
{"i": ["anti - VEGF"], "o": []}
{"i": ["anti - VEGF antibody"], "o": ["CRs or PRs", "efficacy"]}
{"i": ["FCR", "bevacizumab"], "o": []}
{"i": ["FCR"], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["cardiovascular toxicity ."]}
{"i": ["bevacizumab"], "o": ["Cardiovascular toxicity"]}
{"i": ["chemotherapy"], "o": ["hypertension , congestive heart failure , and arterial and venous thromboembolic disease ."]}
{"i": [], "o": ["complications"]}
{"i": [], "o": ["cardiovascular toxicities"]}
{"i": ["PCR - B"], "o": ["achievement of CR"]}
{"i": ["bevacizumab"], "o": ["baseline CCL - 3 plasma levels", "response rate"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["CCL - 3 levels"]}
{"i": ["Ibrutinib or Idelalisib", "bevacizumab"], "o": ["plasma levels", "CCL - 3 and CCL - 4"]}
{"i": [], "o": ["CCL - 3 and CCL - 4 levels"]}
{"i": ["bevacizumab"], "o": ["CCL - 3 and CCL - 4"]}
{"i": [], "o": []}
{"i": [], "o": ["VEGF levels"]}
{"i": [], "o": ["VEGF levels"]}
{"i": ["bevacizumab"], "o": []}
{"i": [], "o": ["cardiovascular toxicity"]}
{"i": ["CIT"], "o": []}
{"i": ["chemoimmunotherapy", "CIT", "anti - VEGF therapy"], "o": ["progression - free and treatment - free survival", "complete response rates"]}
{"i": ["ibrutinib or Idelalisib"], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["renal and hepatic function", "ECOG performance status"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["pentostatin", "rituximab", "cyclophosphamide"], "o": []}
{"i": [], "o": []}
{"i": ["PCR alone", "PCR in combination with bevacizumab ( PCR - B"], "o": []}
{"i": ["PCR in combination with bevacizumab"], "o": []}
{"i": ["PCR alone"], "o": []}
{"i": ["sulfamethoxazole - trimethoprim or alternative ) and herpes zoster ( valacyclovir or alternative )"], "o": []}
{"i": ["allopurinol"], "o": []}
{"i": ["Pegfilgrastim"], "o": []}
{"i": [], "o": ["Platelet and hemoglobin adverse events", "hematologic toxicity ."]}
{"i": [], "o": ["adverse events"]}
{"i": [], "o": ["Toxicity"]}
{"i": [], "o": []}
{"i": [], "o": ["nodular partial remission", "complete response ( CR"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["VEGF , b - FGF , anti -[ thrombospondin ( TSP )- 1 ], chemokine ligand ( CCL )- 3"]}
{"i": [], "o": ["VEGF ( isoform 165 ), b - FGF , CCL - 3 and CCL - 4"]}
{"i": [], "o": ["CD38 , ZAP - 70 , IGHV mutation status , and recurrent cytogenetic abnormalities"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["rate of complete response ."]}
{"i": [], "o": ["CR"]}
{"i": [], "o": []}
{"i": [], "o": ["rate of MRD negative remissions"]}
{"i": [], "o": []}
{"i": [], "o": ["Progression - free survival ( PFS )"]}
{"i": [], "o": ["Treatment - free survival ( TFS )"]}
{"i": [], "o": ["Overall survival ( OS )"]}
{"i": [], "o": ["time to event"]}
{"i": [], "o": []}
{"i": [], "o": ["cytokine values"]}
